Antiemetic medication efficacy during EPOCH and R-EPOCH treatment.

Megan K FlemingAllison CarrJunan LiJordan D LundbergKerry A Rogers

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

This study illustrates the inadequacy of current institutional standard for CINV prophylaxis for patients receiving EPOCH and R-EPOCH, highly emetogenic chemotherapy regimens. With nearly half of included patients experiencing CINV events, and most initially receiving more than our standard prophylaxis, changes to our standard antiemetics used with this chemotherapy regimen are needed.

Keyphrases

chemotherapy induced
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
locally advanced
prognostic factors
peritoneal dialysis
healthcare
radiation therapy
rectal cancer